
Prelude Therapeutics Incorporated: stock overview
Price
$3.23
November 20, 2026Market cap $333M
What Ploutos Investor adds for Prelude Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Prelude Therapeutics had revenue of $22M over the last 12 months and a net loss of $53M. It holds more cash than debt, by $140M. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.
Its SEC filings- Market cap
- $333M
- 103M shares
- P/E
- –
- Revenue, 12 months
- $22M
- +73.4% a year over 1 years
- Net margin
- -247.1%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
2 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap
- $333M
- Enterprise value
- $193M
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- 9.0
- P/B
- 2.7
- FCF yield
- –
- Earnings yield
- –
Profitability
- Operating margin
- -283.9%
- Net margin
- -247.1%
- ROIC
- -54.3%
- ROIC, 5-year average
- -102.2%
- ROE
- -59.9%
Growth
- Revenue, yearly change
- +73.4%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +73.4%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $140M
- Total debt
- $18M
- Of which operating leases
- $18M
- Net cash
- $140M
- Net debt / EBITDA
- –
- Interest cover
- –
- Current ratio
- 4.20
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +14.2%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Prelude Therapeutics Inc
- CIK
- 1678660
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 103M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with PRLD
- JNJJohnson & Johnson+0,00%Compare with PRLD
- ABBVAbbVie+0,00%Compare with PRLD
- UNHUnitedHealth+0,00%Compare with PRLD
- MRKMerck & Company+0,00%Compare with PRLD
- AMGNAmgen+0,00%Compare with PRLD
- TMOThermo Fisher Scientific+0,00%Compare with PRLD
- ABTAbbott Laboratories+0,00%Compare with PRLD
The full analysis
What do Prelude Therapeutics's filings show?
These are Prelude Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is PRLD's market cap?
Prelude Therapeutics Incorporated's market cap is $333M, at a price of $3.23 on November 20, 2026 and 103M shares.
How much revenue does PRLD have?
Prelude Therapeutics had revenue of $22M over the last 12 months. Over the last 1 years it changed by +73.4% a year on average.
Does PRLD pay a dividend?
No. Prelude Therapeutics paid no regular dividend over the last 12 months.
Where do the figures come from?
From Prelude Therapeutics Incorporated's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.